 |
N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Pancreatic Cancer |
| USA Market Approval | USA |
| USA Designation Date | 2010-01-29 00:00:00 |
| Sponsor | EMD Serono, Inc.;1 Technology Place;Rockland, Massachusetts, 02370 |
